804 related articles for article (PubMed ID: 11693467)
1. Lansoprazole: an update of its place in the management of acid-related disorders.
Matheson AJ; Jarvis B
Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
[TBL] [Abstract][Full Text] [Related]
2. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
Langtry HD; Wilde MI
Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
[TBL] [Abstract][Full Text] [Related]
3. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Cheer SM; Prakash A; Faulds D; Lamb HM
Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
[TBL] [Abstract][Full Text] [Related]
4. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
Langtry HD; Wilde MI
Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
[TBL] [Abstract][Full Text] [Related]
5. Rabeprazole: an update of its use in acid-related disorders.
Carswell CI; Goa KL
Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
[TBL] [Abstract][Full Text] [Related]
6. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.
Wilde MI; McTavish D
Drugs; 1994 Jul; 48(1):91-132. PubMed ID: 7525198
[TBL] [Abstract][Full Text] [Related]
7. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
[TBL] [Abstract][Full Text] [Related]
8. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Langtry HD; Markham A
Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
[TBL] [Abstract][Full Text] [Related]
9. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
Spencer CM; Faulds D
Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
[TBL] [Abstract][Full Text] [Related]
10. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
Gremse DA
Expert Opin Pharmacother; 2001 Oct; 2(10):1663-70. PubMed ID: 11825309
[TBL] [Abstract][Full Text] [Related]
11. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
Fitton A; Wiseman L
Drugs; 1996 Mar; 51(3):460-82. PubMed ID: 8882382
[TBL] [Abstract][Full Text] [Related]
12. Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
Howden CW
Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S5-11. PubMed ID: 10597118
[TBL] [Abstract][Full Text] [Related]
13. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Barradell LB; Faulds D; McTavish D
Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
15. Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?
O'Connor HJ; McLoughlin R; Kelly S; Laundon J; Cunnane K
Aliment Pharmacol Ther; 1998 Mar; 12(3):273-6. PubMed ID: 9570262
[TBL] [Abstract][Full Text] [Related]
16. Esomeprazole: a review of its use in the management of acid-related disorders.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
Treiber G; Wittig J; Ammon S; Walker S; van Doorn LJ; Klotz U
Arch Intern Med; 2002 Jan; 162(2):153-60. PubMed ID: 11802748
[TBL] [Abstract][Full Text] [Related]
18. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
[TBL] [Abstract][Full Text] [Related]
19. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial.
Lai KC; Lam SK; Chu KM; Hui WM; Kwok KF; Wong BC; Hu HC; Wong WM; Chan OO; Chan CK
Aliment Pharmacol Ther; 2003 Oct; 18(8):829-36. PubMed ID: 14535877
[TBL] [Abstract][Full Text] [Related]
20. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]